1-8 of 8
Werner Engl, PhD Cstat
Close
Sort by
Journal Articles

Efficacy and Safety Results from a Phase 3b, Open-Label, Multicenter, Continuation Study of Rurioctocog Alfa Pegol for Prophylaxis in Previously Treated Patients with Severe Hemophilia A

Eric S. Mullins, MD, Barbara A Konkle, Catherine E. McGuinn, MD, Werner Engl, PhD CStat, Srilatha D. Tangada, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2483.
https://doi.org/10.1182/blood-2018-99-110190
Published: 2018
Journal Articles

Evaluation of the Safety, Immunogenicity, and Hemostatic Efficacy of Nonacog Gamma (BAX326) in Previously Treated and Naïve Patients with Severe or Moderately Severe Hemophilia B: A Continuation Study

Jerzy Windyga, Oleksandra Stasyshyn, MD PhD, Werner Engl, PhD CStat, Srilatha D. Tangada, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1197.
https://doi.org/10.1182/blood-2018-99-111295
Published: 2018
Journal Articles

Pegylated Full-Length Recombinant Factor VIII with Extended Half-Life in Previously Treated Pediatric Patients with Hemophilia Α: Efficacy of Prophylaxis and Treatment By Time (of Day/of Week) of Occurrence of Bleeding

Eric S. Mullins, MD, Christine M. Knoll, MD, Amy L. Dunn, MD, Werner Engl, PhD Cstat, Marlies Sharkhawy, MA, Brigitt E. Abbuehl, MD
Journal: Blood
Blood (2016) 128 (22): 1409.
https://doi.org/10.1182/blood.V128.22.1409.1409
Published: 2016
Journal Articles

Target Joint Bleeding in Pediatric Patients with Hemophilia Α Receiving Twice Weekly Prophylaxis with a Pegylated Full-Length Recombinant Factor VIII with Extended Half-Life

Amy L. Dunn, MD, Alexis A. Thompson, MD MPH, Werner Engl, PhD Cstat, Marlies Sharkhawy, MA, Brigitt E. Abbuehl, MD
Journal: Blood
Blood (2016) 128 (22): 3778.
https://doi.org/10.1182/blood.V128.22.3778.3778
Published: 2016
Journal Articles

Target Joint Status in Patients with Hemophilia a during 18 Consecutive Months of Prophylaxis with a Pegylated Full-Length Recombinant Factor VIII with Extended Half-Life

Werner Engl, PhD Cstat, Lisa Patrone, PhD, Brigitt E. Abbuehl, MD
Journal: Blood
Blood (2016) 128 (22): 2592.
https://doi.org/10.1182/blood.V128.22.2592.2592
Published: 2016
Journal Articles

Immunogenicity of BAX 855 in Previously Treated Patients with Congenital Severe Hemophilia Α

Frank Michael Horling, PhD, Peter Allacher, PhD, Herwig Koppensteiner, PhD, Werner Engl, PhD Cstat, Fritz Scheiflinger, PhD, Brigitt E. Abbuehl, MD, Birgit M Reipert, PhD
Journal: Blood
Blood (2016) 128 (22): 2594.
https://doi.org/10.1182/blood.V128.22.2594.2594
Published: 2016
Journal Articles

An Evaluation of Safety with an Extended Half-Life, Pegylated, Full-Length Recombinant Factor VIII (BAX 855) in the Treatment of 243 Patients with Hemophilia a

Werner Engl, PhD Cstat, Lisa Patrone, PhD, Dyck-Jones Jacqueline, PhD, Srilatha D. Tangada, PhD, Brigitt E. Abbuehl, MD
Journal: Blood
Blood (2016) 128 (22): 3801.
https://doi.org/10.1182/blood.V128.22.3801.3801
Published: 2016
Journal Articles

Modelling FVIII Levels for Prediction of Zero Spontaneous-Joint Bleeding in a Cohort of Severe Hemophilia a Subjects with Target Joints Initiated on Tertiary Prophylaxis

Kathelijn Fischer, MD PhD MSc, Pratima Chowdary, FRCPath, MRCPath, MRCP, MD, Peter Collins, MD, Amy Cotterill, PhD, Barbara Konkle, MD, Victor S. Blanchette, FRCP, FRCPC, Steven W. Pipe, MD, Martin Wolfsegger, Cstat (RSS), Werner Engl, PhD Cstat, Jimena V Goldstine, PhD, Leonard A. Valentino, MD FAAP, Gerald Spotts, PhD
Journal: Blood
Blood (2016) 128 (22): 2576.
https://doi.org/10.1182/blood.V128.22.2576.2576
Published: 2016